NEWLY DIAGNOSED FLT3 MUTATED AML

Clinical trials for NEWLY DIAGNOSED FLT3 MUTATED AML explained in plain language.

Never miss a new study

Get alerted when new NEWLY DIAGNOSED FLT3 MUTATED AML trials appear

Sign up with your email to follow new studies for NEWLY DIAGNOSED FLT3 MUTATED AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New drug shows promise in leukemia battle

Disease control Completed

This study tested a new drug, crenolanib, against an existing drug, midostaurin, in adults aged 18-60 with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). Participants received one of the two drugs alongside standard chemotherapy and, if eligible, a bone mar…

Matched conditions: NEWLY DIAGNOSED FLT3 MUTATED AML

Phase: PHASE3 • Sponsor: Arog Pharmaceuticals, Inc. • Aim: Disease control

Last updated Apr 26, 2026 19:38 UTC

NEWLY DIAGNOSED FLT3 MUTATED AML

Get alerted when new NEWLY DIAGNOSED FLT3 MUTATED AML trials appear

New drug shows promise in leukemia battle